lymphoma
Conditions
Interventions
Observation group:Chidamide Combined with R-CHOP Regimen
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. Pathological biopsy diagnosis was consistent with B-cell lymphoma according to WHO 2016 classification criteria, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) grade I-III, marginal zone B-cell lymphoma (MALT), lymphoplasmacytic lymphoma (LPL), small lymphocytic B-cell lymphoma (SLL), mantle cell lymphoma (MCL), transforming lymphoma (TL), etc.; 3. Epigenetic gene mutations were detected by high throughput sequencing in pathological tissues or peripheral blood: EZH2, TET2, KMT2C(MLL3), KMT2D(MLL2), MEF2B, EP300, CREBBP, IDH2, PHF6, SF3B1, SPEN; 4. Measurable lesions on cross-sectional imaging recorded by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) (defined as the presence of at least one two-dimensional measurable lesion with a maximum cross-sectional diameter (GTD) >= 1.5cm, without considering the diameter of the short axis); 5. The physical status of the Eastern Cancer Collaboration Group (ECOG) was less than 2 points; 6. Adequate liver function: bilirubin =35mL/min as calculated by Cockcroft-Gault formula; 7. Voluntary participation, willingness to provide the above treatment data, signed and dated informed consent.
Exclusion criteria
Exclusion criteria: 1. Enrolled in other clinical trials; 2. Being treated with immunosuppressive therapy for other diseases; 3. Had received other treatments for lymphoma before enrollment; 4. Complicated with other malignant tumors; 5. The researcher decided that it is not suitable to participate in this study; 6. Severe mental or neurological conditions that affect informed consent and/or expression or observation of adverse reactions; 7. Patients could not be followed up; 8. Pregnant and lactating patients and patients of childbearing age who do not want to take contraceptive measures; 9. Active infection of HBV and HCV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Objective response rate; | — |
Countries
China
Contacts
Public ContactJing Hongmei
Peking University Third Hospital
Outcome results
None listed